Impact BioMedical
19 hedge funds and large institutions have $1.76M invested in Impact BioMedical in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
0% more funds holding
Funds holding: 19 → 19 (0)
21% less capital invested
Capital invested by funds: $2.23M → $1.76M (-$470K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
26.99% less ownership
Funds ownership: 30.55% → 3.56% (-27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$59.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$29.3K |
| 3 |
Jane Street
New York
|
+$14.5K |
| 4 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$2.5K |
| 5 |
Morgan Stanley
New York
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$17.8K |
| 2 |
Two Sigma Investments
New York
|
-$12K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$5.01K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$4.6K |
| 5 |
Citigroup
New York
|
-$209 |
IBO Hedge Fund Activity: Q2 2026 in Review
19 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q2 2026, worth a combined $1.76M — down 21% from $2.23M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new IBO positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Capital Management, adding an estimated $59.5K. The largest seller was UBS Group, cutting an estimated $17.8K.
- 19 institutional investors held Impact BioMedical (IBO) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $1.76M of Impact BioMedical stock for Q2 2026, down 21% quarter-over-quarter.
- 2 funds opened new Impact BioMedical positions in Q2 2026 and 1 closed out, a net change of +1 holder.
- The largest Impact BioMedical buyer in Q2 2026 was Vanguard Capital Management, an estimated $59.5K added.
- The largest Impact BioMedical seller in Q2 2026 was UBS Group, an estimated $17.8K sold.
Based on aggregated 13F filings for Q2 2026.